0.307
price down icon14.72%   -0.053
after-market After Hours: .30 -0.007 -2.28%
loading
Eterna Therapeutics Inc stock is traded at $0.307, with a volume of 30.45M. It is down -14.72% in the last 24 hours and down -71.31% over the past month.
See More
Previous Close:
$0.36
Open:
$0.4746
24h Volume:
30.45M
Relative Volume:
54.39
Market Cap:
$15.77M
Revenue:
$598.00K
Net Income/Loss:
$-44.93M
P/E Ratio:
-0.0544
EPS:
-5.64
Net Cash Flow:
$-17.32M
1W Performance:
-30.23%
1M Performance:
-71.31%
6M Performance:
-84.38%
1Y Performance:
-74.63%
1-Day Range:
Value
$0.30
$0.4988
1-Week Range:
Value
$0.30
$0.4988
52-Week Range:
Value
$0.30
$2.625

Eterna Therapeutics Inc Stock (ERNA) Company Profile

Name
Name
Eterna Therapeutics Inc
Name
Phone
(212) 582-1199
Name
Address
1035 CAMBRIDGE STREET, CAMBRIDGE
Name
Employee
0
Name
Twitter
Name
Next Earnings Date
2024-11-11
Name
Latest SEC Filings
Name
ERNA's Discussions on Twitter

Compare ERNA with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
ERNA
Eterna Therapeutics Inc
0.307 15.77M 598.00K -44.93M -17.32M -8.31
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
463.98 119.49B 10.63B -479.80M -1.35B -1.99
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
754.26 82.89B 13.85B 4.65B 3.32B 40.41
Biotechnology icon
ARGX
Argen X Se Adr
624.96 37.37B 1.86B -40.29M -1.28B -0.85
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
254.72 32.85B 2.09B -332.26M 16.06M -2.62
Biotechnology icon
BNTX
Biontech Se Adr
114.70 27.50B 3.30B -501.07M 1.03B -2.1146

Eterna Therapeutics Inc Stock (ERNA) Latest News

pulisher
09:00 AM

Eterna’s ERNA-101 to be studied in ovarian and breast cancer models - BioWorld Online

09:00 AM
pulisher
02:45 AM

Eterna Therapeutics to test cancer cell therapy with MD Anderson By Investing.com - Investing.com Canada

02:45 AM
pulisher
Dec 03, 2024

Eterna Therapeutics Launches Research to Evaluate its Lead - GlobeNewswire

Dec 03, 2024
pulisher
Dec 03, 2024

Eterna Therapeutics Launches Research to Evaluate Its Lead Induced Mesenchymal Stem Cell Therapy Candidate's (Erna-101) Ability to Induce and Modulate Antitumor Immunity in Ovarian Cancer and Breast Cancer Models - Marketscreener.com

Dec 03, 2024
pulisher
Dec 02, 2024

ERNA stock touches 52-week low at $0.4 amid market challenges - Investing.com

Dec 02, 2024
pulisher
Dec 02, 2024

ERNA stock touches 52-week low at $0.4 amid market challenges By Investing.com - Investing.com South Africa

Dec 02, 2024
pulisher
Nov 26, 2024

Eterna Therapeutics initiates $1 million stock buyback By Investing.com - Investing.com South Africa

Nov 26, 2024
pulisher
Nov 25, 2024

Eterna Therapeutics initiates $1 million stock buyback - Investing.com India

Nov 25, 2024
pulisher
Nov 25, 2024

Eterna Therapeutics Announces Up to $1 Million Stock Repurchase Program - GlobeNewswire

Nov 25, 2024
pulisher
Nov 24, 2024

StockNews.com Initiates Coverage on Brooklyn ImmunoTherapeutics (NYSE:BTX) - Defense World

Nov 24, 2024
pulisher
Nov 23, 2024

ERNA Stock Hits 52-Week Low at $0.52 Amid Market Challenges - Investing.com Australia

Nov 23, 2024
pulisher
Nov 22, 2024

ERNA Stock Hits 52-Week Low at $0.52 Amid Market Challenges By Investing.com - Investing.com South Africa

Nov 22, 2024
pulisher
Nov 16, 2024

Brooklyn ImmunoTherapeutics (NYSE:BTX) Coverage Initiated at StockNews.com - Defense World

Nov 16, 2024
pulisher
Nov 15, 2024

ERNA Stock Hits 52-Week Low at $0.83 Amid Market Challenges - Investing.com India

Nov 15, 2024
pulisher
Nov 14, 2024

Eterna Therapeutics regains Nasdaq compliance, focuses on cancer therapy - Investing.com

Nov 14, 2024
pulisher
Nov 14, 2024

Eterna Therapeutics Regains Compliance with NASDAQ for Continued Listing - The Manila Times

Nov 14, 2024
pulisher
Nov 14, 2024

Eterna Therapeutics Regains Nasdaq Compliance, Advances Cancer Treatment Pipeline | ERNA Stock News - StockTitan

Nov 14, 2024
pulisher
Nov 14, 2024

Brooklyn ImmunoTherapeutics (NYSE:BTX) Now Covered by StockNews.com - MarketBeat

Nov 14, 2024
pulisher
Nov 07, 2024

Lineage Cell Therapeutics to Report Third Quarter 2024 Financial Results and Provide Business Update on November 14, 2024 - Business Wire

Nov 07, 2024
pulisher
Nov 05, 2024

Eterna Therapeutics shareholder Charles Cherington sells $6.54m in stock - Investing.com

Nov 05, 2024
pulisher
Nov 05, 2024

Eterna Therapeutics shareholder Charles Cherington sells $6.54m in stock By Investing.com - Investing.com UK

Nov 05, 2024
pulisher
Nov 01, 2024

NTN Buzztime Enters Into Material Definitive Agreement and Reports Voting Results at Annual Meeting Eterna Therapeutics Inc., a company listed on the Nasdaq Stock Market under the symbol ERNA, recently filed a Form 8-K with the Securities - Defense World

Nov 01, 2024
pulisher
Oct 30, 2024

Eterna Therapeutics Completes Strategic Financial Restructuring with the Aim to Accelerate its Developmental Activities and Long-Term Success - GlobeNewswire

Oct 30, 2024
pulisher
Oct 29, 2024

Eterna Therapeutics announces share issuance and executive agreements By Investing.com - Investing.com South Africa

Oct 29, 2024
pulisher
Oct 29, 2024

Eterna Therapeutics announces share issuance and executive agreements - Investing.com India

Oct 29, 2024
pulisher
Oct 29, 2024

Brooklyn ImmunoTherapeutics (NYSE:BTX) Earns Hold Rating from Analysts at StockNews.com - MarketBeat

Oct 29, 2024
pulisher
Oct 18, 2024

Eterna, Factor announce license, collaboration agreement - Yahoo Finance

Oct 18, 2024
pulisher
Oct 18, 2024

Factor Bioscience and Eterna Therapeutics Announce Exclusive License and Collaboration Agreement to Accelerate Cell Therapy Development for Oncology, Autoimmune, and Rare Diseases - BioSpace

Oct 18, 2024
pulisher
Oct 17, 2024

Eterna secures exclusive license for cell therapy tech - Investing.com India

Oct 17, 2024
pulisher
Oct 17, 2024

Eterna secures exclusive license for cell therapy tech By Investing.com - Investing.com UK

Oct 17, 2024
pulisher
Oct 17, 2024

Eterna Therapeutics and Factor Bioscience Announce Exclusive License and Collaboration Agreement to Accelerate Cell Therapy Development for Oncology, Autoimmune, and Rare Diseases - GlobeNewswire

Oct 17, 2024
pulisher
Oct 06, 2024

Eterna Therapeutics : Presentation (ZwKlOLVsGrYSwatS Zv 5rrVsGrYSwY0B EternaTherapeutics FactSheet October03%2C2024Final v1) - Marketscreener.com

Oct 06, 2024
pulisher
Oct 01, 2024

Eterna Therapeutics Inc. (NASDAQ:ERNA) Sees Large Growth in Short Interest - Defense World

Oct 01, 2024
pulisher
Sep 27, 2024

Eterna Therapeutics inks new license agreement, ends previous Factor Bioscience deals - Investing.com

Sep 27, 2024
pulisher
Sep 27, 2024

Eterna Therapeutics Strikes Key Deal for Disease-Fighting Tech - TipRanks

Sep 27, 2024
pulisher
Sep 27, 2024

Eterna Therapeutics Inc: A Year of Highs, Lows, and Market Resilience - The InvestChronicle

Sep 27, 2024
pulisher
Sep 23, 2024

Eterna Therapeutics faces Nasdaq delisting over equity shortfall By Investing.com - Investing.com Canada

Sep 23, 2024
pulisher
Sep 23, 2024

Eterna Therapeutics faces Nasdaq delisting over equity shortfall - Investing.com

Sep 23, 2024
pulisher
Sep 23, 2024

Eterna Therapeutics Inc. announced that it expects to receive $5.037748 million in funding - Marketscreener.com

Sep 23, 2024
pulisher
Sep 11, 2024

Brooklyn ImmunoTherapeutics (NYSE:BTX) Now Covered by Analysts at StockNews.com - Defense World

Sep 11, 2024
pulisher
Sep 03, 2024

Brooklyn ImmunoTherapeutics (NYSE:BTX) Research Coverage Started at StockNews.com - MarketBeat

Sep 03, 2024
pulisher
Aug 22, 2024

Eterna Therapeutics (NASDAQ:ERNA) Shares Up 2.4% - Defense World

Aug 22, 2024
pulisher
Aug 20, 2024

Eterna Therapeutics sets September 27 for annual meeting By Investing.com - Investing.com Australia

Aug 20, 2024
pulisher
Aug 19, 2024

Eterna Therapeutics sets September 27 for annual meeting - Investing.com

Aug 19, 2024

Eterna Therapeutics Inc Stock (ERNA) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$21.65
price down icon 0.23%
$74.62
price up icon 3.60%
$41.63
price down icon 2.23%
$374.40
price up icon 1.52%
$199.09
price down icon 3.36%
$114.70
price down icon 0.77%
Cap:     |  Volume (24h):